You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
Register for free to read this article
As a service to the community, this article is available for free. Existing users log in.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
This STKE Focus Issue on processes, targets, and opportunities in drug discovery is part of a coordinated effort to cover a broad range of topics related to drug discovery in Science's multiple online products and in a special issue of Science itself. STKE features three Perspectives and one Review that highlight drug development and signaling targets for therapeutic development. Shen describes the production of natural bioactive products by combinatorial biosynthesis in bacteria. Philips describes anticancer therapies aimed at the oncogenic guanosine triphosphatase Ras, and Kaelin discusses whether common cancers are likely to yield to single anticancer agents and echo the rousing success of the kinase inhibitor Gleevec. Charney and Manji discuss how an increased understanding of the underlying pathways could lead to novel potential therapies for treating depression.
